<DOC>
	<DOCNO>NCT02272647</DOCNO>
	<brief_summary>Progesterone amplify estrogen-stimulated Growth Hormone ( GH ) secretion postmenopausal woman . Preliminary data seek estimate statistical power detailed study hypothesis .</brief_summary>
	<brief_title>Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion Older Women</brief_title>
	<detailed_description>The systemic availability orderly secretion pattern GH sex steroid decline healthy age men woman . The combined change substantial clinical implication aging-related physical frailty , diminish aerobic capacity , sarcopenia , osteopenia , visceral adiposity , glucose intolerance , reduce psychosocial wellbeing . Whereas androgen consider main trophic ( anabolic ) sex steroid , recent data demonstrate certain tissue respond principally GH testosterone-derived estradiol , Estrogen ( E2 ) ( e.g . bone , brain , liver pituitary ) . In principle , frailty may thus associate dual GH sex-steroid deficiency . Additionally , young , old healthy woman secrete significant amount progesterone approximately 14 day luteal phase every menstrual cycle . When GH level rise nearly two fold , investigator hypothesize progesterone potentiates GH response E2 . This hypothesis arise scattered indirect study often use synthetic progestin partial androgen agonism , instead progesterone per se . Because basis estimate statistical power novel paradigm , 40 woman , 10 4 group , study . The pilot data use calculate statistical power definitive R01-based investigation gender-specific distinction estrogen-regulated pituitary-hormone secretion .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>woman age 50 80 postmenopausal define : combination follow Hormonally postmenopausal 1 year Lh great 15 IU/L , FSH great 30 IU/L Total hysterectomy oophorectomy great one year Hysterectomy ovaries preserve hormone level : Lh &gt; 15 IU/L , FSH &gt; 30 IU/L Following laboratory result normal range , unless PI approve range value . BMI 18 35 structural hypothalamopituitarygonadal disease endocrinopathy ( diseases involve follow organ pituitary , thyroid , adrenal , ovary , testis pancreas ) , primary thyroid failure receive replacement recent ( within 2 week ) estrogen , progestin , anabolic steroid glucocorticoid use clinically significant ECG abnormality determine study team physician obstructive uropathy history stroke history MI angina acute chronic systemic disease recent transmeridian travel ( traverse 3 time zone within 7 day admission ) current night shift work concurrent use neuropsychiatric medication alcohol drug abuse , current within 2 year history depression , psychosis , mania weight gain loss ( 2 kg 3 week ) BMI &gt; 35 kg/m2 anemia , hemoglobin le 12.5 g/dl abnormal hepatorenal function , creatinine outside normal range , ALT great two time normal range biochemical chemistry lab result physician acceptable range history deepvein thrombophlebitis history Congestive Heart Failure , cardiac arrhythmia , medication use treat cardiac arrhythmia know allergy estradiol valerate , castor oil sesame oil history smoking within last 2 year untreated gall bladder disease lack voluntary , write informed consent history carcinoma exclude localize basal cell squamous cell , include woman know , suspected history breast cancer clinically postmenopausal woman allergy nut enrol study .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Normal Healthy Volunteers</keyword>
</DOC>